Group 1 - Zoetis Inc. primarily operates in the companion animal sector, focusing on high-growth and high-margin areas such as dermatology, parasiticides, and osteoarthritis pain management for cats and dogs [1]

Wall Street analysts expect Zoetis (ZTS) to post quarterly earnings of $1.61 per share in its upcoming report, which indicates a year-over-year increase of 3.2%. Revenues are expected to be $2.4 billion, up 1.7% from the year-ago quarter. The current level reflects an upward revision of 0.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. Analysts predict that ...